Lyon & Lyon LLP
RNase L activators and antisense oligonucleotides effective to treat RSV infections
The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an "antisense oligonucleotide") coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.
The Cleveland Clinic Foundation The United States of America as represented by the Department of Health and Human Services
C C C C C C A A A
C12N C07H C12N C12N C12N C12N A61K A61P A61K
additional inventional inventional additional additional additional additional inventional inventional
Nick Mario Wei Guiying Robert Hugh Paul F. Mark R.
Cirino Xiao Li Silverman Torrence Player